- Home
- WIA vs ANTX Comparison
WIA vs ANTX Comparison
Compare WIA & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WIA | ANTX |
|---|---|---|
| Founded | 2003 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.7M | 172.9M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | WIA | ANTX |
|---|---|---|
| Price | $7.93 | $5.66 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 23.1K | ★ 208.0K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 12.29% | N/A |
| EPS Growth | N/A | ★ 32.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.90 | $1.00 |
| 52 Week High | $8.54 | $7.19 |
Technical Indicators
Market Signals| Indicator | WIA | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 38.44 | 53.33 |
| Support Level | N/A | $3.91 |
| Resistance Level | $8.03 | $7.05 |
| Average True Range (ATR) | 0.05 | 0.45 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 22.27 | 11.54 |
Price Performance
Historical ComparisonAbout WIA Western Asset Inflation-Linked Income Fund
Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation. Under normal market conditions and at the time of purchase, the Fund will invest at least 80% of its total managed assets in inflation-linked securities and at least 60% of its total managed assets in U.S. Treasury Inflation Protected Securities (TIPS). The Fund may also invest up to 40% of its total managed assets in non-U.S. dollar investments.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.